Actively Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction
Led by Xinjiang Medical University · Updated on 2026-01-05
1000
Participants Needed
2
Research Sites
308 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are: 1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
CONDITIONS
Official Title
The Association Between Primary Aldosteronism and Cognitive Dysfunction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged �3E= 40 years
- Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines
- Ability to understand and cooperate with comprehensive neuropsychological assessment
- Voluntary participation and provision of written informed consent
You will not qualify if you...
- Significant visual, hearing, or motor impairment that prevents completion of cognitive testing
- History of major neurological disorders such as stroke, Parkinson's disease, intracranial tumor, or severe traumatic brain injury
- History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications
- Diagnosis of secondary hypertension other than PA
- Unwillingness to participate by the patient or their legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, China, 610000
Actively Recruiting
2
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 830000
Actively Recruiting
Research Team
X
Xiang Xie, PhD
CONTACT
K
Kaige Feng
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here